PRECLINICAL EFFICACY OF A PROTOTYPE DNA VACCINE - ENHANCED PROTECTION AGAINST ANTIGENIC DRIFT IN INFLUENZA-VIRUS

被引：265

作者：

DONNELLY, JJ

FRIEDMAN, A

MARTINEZ, D

MONTGOMERY, DL

SHIVER, JW

MOTZEL, SL

ULMER, JB

LIU, MA

机构：

[1] MERCK SHARP & DOHME LTD, DEPT VIRUS & CELL BIOL, RES LABS, West Point, PA 19486 USA

[2] MERCK SHARP & DOHME LTD, DEPT LAB ANIM RESOURCES, RES LABS, West Point, PA 19486 USA

来源：

NATURE MEDICINE | 1995年 / 1卷 / 06期

关键词：

D O I：

10.1038/nm0695-583

中图分类号：

Q5 [生物化学]; Q7 [分子生物学];

学科分类号：

071010 ; 081704 ;

摘要：

Vaccination with plasmid DNA expression vectors encoding foreign proteins elicits antibodies and cell-mediated immunity and protects against disease in animal models. We report a comparison of DNA vaccines, using contemporary human strains of virus, and clinically licensed (inactivated virus or subvirion) vaccines in preclinical animal models, to better predict their efficacy in humans. Influenza DNA vaccines elicited antibodies in both non-human primates and ferrets and protected ferrets against challenge with an antigenically distinct epidemic human influenza virus more effectively than the contemporary clinically licensed vaccine. These studies demonstrate that DNA vaccines may be more effective, particularly against different strains of virus, than inactivated virus or subvirion vaccines.

引用

页码：583 / 587

页数：5

共 37 条

[31]

Yang Y.P., Cellular immunity to viral antigens limits El-deleted adenoviruses for gene therapy, Proc. Natn. Acad. Sci.U.S.A., 91, pp. 4407-4411, (1994)

[32]

Cooney E.L., Safety of and immunological response to a recombinant vaccinia virus vaccine expressing HIV envelope glycoprotein, Lancet, 337, pp. 567-572, (1991)

[33]

Redfield R.R., Et al., Disseminated vaccinia in a military recruit with human immunodeficiency virus (HIV) disease, New Engl. J. Med, 316, pp. 673-676, (1987)

[34]

Baba T.W., Et al., Pathogenicity of live, attenuated SIV after mucosal infection of neonatal macaques, Science, 267, pp. 1820-1825, (1995)

[35]

Kuwano K., Et al., Active immunization against virus infections due to antigenic drift by induction of cross-reactive cytotoxic T lymphocytes, J. Exp. Med, 169, pp. 1361-1371, (1989)

[36]

Mbawuike I.N., Et al., Influenza A subtype cross-protection after immunization of outbred mice with a purified chimeric NS1JHA2 influenza virus protein, Vaccine, 12, pp. 1431-1448, (1994)

[37]

Fries L.F., Et al., Safety and immunogenicity of a recombinant protein influenza A vaccine in adult human volunteers and protective efficacy against wild-type H1N1 virus challenge, J. Infect. Dis., 167, pp. 593-601

← 1 2 3 4 →